Zed Zha, MD, FAAFP

Future Directions in the Management Atopic Dermatitis in Adult Patients

Video content above in prompted by the following:

Please provide your final thoughts on the future of atopic dermatitis treatments.

Videos

Panelists discuss how the future of atopic dermatitis treatments is evolving with novel biologics, Janus kinase inhibitors, and precision medicine targeting immune pathways. Advances in gene therapy, microbiome modulation, and personalized treatments offer promising long-term management options.

Multispecialty Perspectives on Shared Decision-Making in Atopic Dermatitis Care

Discuss shared decision-making in atopic dermatitis care.

Panelists discuss how shared decision-making in atopic dermatitis care involves collaboration between health care providers and patients, considering individual preferences, values, and treatment goals. This approach enhances treatment adherence and improves outcomes through personalized, informed choices.

Clinical Considerations for Choosing a Systemic Agent for Patients With Atopic Dermatitis

Do you have standard first-line and second-line treatment recommendations for patients that are nonresponsive to topical treatments? How important is patient input in choosing a treatment method?

Panelists discuss how standard first-line treatments for nonresponsive patients often include systemic therapies like corticosteroids or immunomodulators. Second-line options may involve biologics or advanced systemic agents. Patient input is crucial in tailoring treatments to preferences, needs, and risks.

Evaluation of Long-Term Data With JAK Inhibitors

The JADE EXTEND study looked at abrocitinib use in patients who had previously taken dupilumab (Shi 2022). In your experience, does a patient’s positive response to one therapeutic suggest they will also be responsive to a different therapeutic? Similarly, do you find that nonresponders to one therapeutic also are nonresponders to other therapeutics?

In patients who achieved an EASI-75 response with dupilumab, 83/92 (90.2%) achieved EASI-75 with 100 mg abrocitinib and 43/46 (93.5%) achieved EASI-75 with 200 mg abrocitinib after 12 weeks.

In patients who did not achieve an EASI-75 response with dupilumab, 21/31 (67.7%) achieved EASI-75 with 100 mg abrocitinib and 16/20 (80.0%) achieved EASI-75 with 200 mg abrocitinib after 12 weeks.

AEs included nasopharyngitis, nausea, acne, and headache.

Panelists discuss how the JADE EXTEND study (Shi 2022) found that most patients who achieved EASI-75 with dupilumab also responded to abrocitinib. Even some dupilumab nonresponders achieved EASI-75. Adverse events (AEs) included nausea, acne, and headache.

Zed Zha, MD, FAAFP

Articles